GPR37L1 and Hypertension: Regardless, GPR37 and GPR37L1 remain promising therapeutic targets for the treatment of neurodegeneration and hypertension, respectively, although many additional studies will be necessary to confirm the mechanisms and relevance of these receptors to disease.